| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Declan Walsh | Q37829115 |
| P2093 | author name string | Nabila Bennani-Baiti | |
| P2860 | cites work | American Journal of Physiology | Q2160146 |
| Standardization of nomenclature of body composition in weight loss | Q41519168 | ||
| Increased production of tumor necrosis factor by normal immune cells in a model of the humoral hypercalcemia of malignancy | Q41958881 | ||
| Whole body lipid and energy metabolism in the cancer patient | Q42523948 | ||
| Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes | Q42796309 | ||
| Tentative identification of the toxohormones of cancer cachexia: roles of vasopressin, prostaglandin E2 and cachectin-TNF. | Q44061221 | ||
| Cytokine-hormone interactions: tumor necrosis factor alpha impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts | Q44480624 | ||
| Cancer cachexia and tumor growth reduction in Walker 256 tumor-bearing rats supplemented with N-3 polyunsaturated fatty acids for one generation. | Q44553576 | ||
| Adipose tissue in Walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration | Q45111374 | ||
| Metabolic response to enteral food in different phases of cancer cachexia in rats | Q46952219 | ||
| Prognostic factors in advanced gastrointestinal cancer patients with weight loss | Q47230674 | ||
| Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients | Q47272566 | ||
| Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator | Q47296798 | ||
| Tumor growth, weight loss and cytokines in SCID mice | Q47318832 | ||
| Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells | Q47748547 | ||
| Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1beta, -6, and high-mobility-group protein-1 in skeletal muscle | Q47863220 | ||
| The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms | Q48489560 | ||
| The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients | Q48722951 | ||
| Relationship between interleukin-1 and cancer anorexia. | Q50758476 | ||
| Concurrent activity under fixed-interval reinforcement. | Q52363369 | ||
| Increased muscle ubiquitin mRNA levels in gastric cancer patients | Q60403854 | ||
| Evaluation of nutritional status in advanced metastatic cancer | Q60716004 | ||
| Symptoms and prognosis in advanced cancer | Q60716020 | ||
| Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1 | Q61196807 | ||
| Protein synthesis measured in vivo in muscle and liver of cachectic tumor-bearing mice | Q71350122 | ||
| Catabolic factors in cancer cachexia | Q71357633 | ||
| Intravenous interleukin-1-beta-induced inhibition of gastric emptying: involvement of central corticotrophin-releasing factor and prostaglandin pathways in rats | Q71482465 | ||
| Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma | Q71694941 | ||
| Serotoninergic block in the ventromedial nucleus of hypothalamus improves food intake in anorectic tumor bearing rats | Q71754908 | ||
| Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals | Q72545169 | ||
| The cancer anorexia-cachexia syndrome | Q72681492 | ||
| The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer | Q73082097 | ||
| Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia | Q73083849 | ||
| Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure | Q73595578 | ||
| Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states | Q77897177 | ||
| Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial | Q80167138 | ||
| Ratio of n6 to n-3 fatty acids in the diet affects tumor growth and cachexia in Walker 256 tumor-bearing rats | Q83012246 | ||
| The promise of translational physiology | Q94024015 | ||
| Murine models to evaluate novel and conventional therapeutic strategies for cancer | Q24673595 | ||
| Characterization of a cancer cachectic factor | Q28276181 | ||
| Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF) | Q28344353 | ||
| Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes | Q33316844 | ||
| Cachexia in experimental models | Q33696993 | ||
| Leptin | Q33904994 | ||
| Cachexia in cancer patients | Q33962236 | ||
| Systematic review of the treatment of cancer-associated anorexia and weight loss. | Q33991503 | ||
| Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group | Q34057488 | ||
| Purification and characterization of a tumor lipid-mobilizing factor. | Q34066719 | ||
| Central nervous system mechanisms contributing to the cachexia-anorexia syndrome | Q34071892 | ||
| Emergency medicine animal research: does use of randomization and blinding affect the results? | Q34202311 | ||
| Animal models for nutrition in cancer | Q34329032 | ||
| Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. | Q34550960 | ||
| Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies | Q35577488 | ||
| Comparison of treatment effects between animal experiments and clinical trials: systematic review | Q35610097 | ||
| Role of cytokines in regulating feeding behaviour | Q35731334 | ||
| Appetite and cancer-associated anorexia: a review. | Q35745881 | ||
| Interleukin-1beta system in anorectic catabolic tumor-bearing rats | Q35802203 | ||
| Alteration of somatotropic function by proinflammatory cytokines | Q35912023 | ||
| Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones | Q36089013 | ||
| Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia | Q36260781 | ||
| Bench to bedside: the quest for quality in experimental stroke research | Q36416843 | ||
| From bedside to bench and back again: research issues in animal models of human disease | Q36503036 | ||
| Early satiety in cancer patients: a common and important but underrecognized symptom. | Q36506359 | ||
| Summary report of the Standards, Options and Recommendations for malnutrition and nutritional assessment in patients with cancer (1999). | Q37365199 | ||
| ON THE CONDITIONS OF ELICITATION OF CERTAIN EATING REFLEXES. | Q37607067 | ||
| Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients | Q38336764 | ||
| Comparison of animal models for head and neck cancer cachexia | Q40070814 | ||
| The past, present and future of multi-targeted cancer treatment "naturally": food for thought | Q40087861 | ||
| Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. | Q40343588 | ||
| Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. | Q40819792 | ||
| Cracking the riddle of cancer anorexia | Q41233951 | ||
| The effects of diet, ad libitum overfeeding, and moderate dietary restriction on the rodent bioassay: the uncontrolled variable in safety assessment | Q41310710 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | animal disease model | Q64732998 |
| P304 | page(s) | 1451-1463 | |
| P577 | publication date | 2010-08-17 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Animal models of the cancer anorexia-cachexia syndrome | |
| Animal models of the cancer anorexia–cachexia syndrome | |||
| P478 | volume | 19 |
| Q38493100 | A role of active brown adipose tissue in cancer cachexia? |
| Q39745261 | Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. |
| Q33813605 | Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15. |
| Q36847549 | CCAAT/enhancer binding protein beta protects muscle satellite cells from apoptosis after injury and in cancer cachexia |
| Q99409969 | Characterization of cachexia in the human fibrosarcoma HT-1080 mouse tumour model |
| Q91610296 | Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol |
| Q38451282 | Developing models for cachexia and their implications in drug discovery |
| Q64104428 | Development and characterization of a cancer cachexia model employing a rare human duodenal neuroendocrine carcinoma-originating cell line |
| Q36737744 | Development of an UPLC mass spectrometry method for measurement of myofibrillar protein synthesis: application to analysis of murine muscles during cancer cachexia |
| Q26738879 | Diet composition as a source of variation in experimental animal models of cancer cachexia |
| Q35915005 | Dietary leucine supplementation minimises tumour-induced damage in placental tissues of pregnant, tumour-bearing rats |
| Q90103137 | Drosophila as a Model for Tumor-Induced Organ Wasting |
| Q38270323 | Evidence and mechanisms of fat depletion in cancer |
| Q50201348 | Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia. |
| Q91604235 | IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm |
| Q37493688 | Leucine-rich diet supplementation modulates foetal muscle protein metabolism impaired by Walker-256 tumour. |
| Q91984670 | Macrophages protect against loss of adipose tissue during cancer cachexia |
| Q35332991 | Malignant Drosophila tumors interrupt insulin signaling to induce cachexia-like wasting |
| Q49544329 | Metabolic Changes During Cancer Cachexia Pathogenesis. |
| Q92767459 | Metastasis and cachexia: alongside in clinics, but not so in animal models |
| Q28068034 | Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans? |
| Q38589651 | N-Methyl-N-nitrosourea as a mammary carcinogenic agent. |
| Q39042463 | New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. |
| Q33834933 | Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia |
| Q38895420 | Pioglitazone treatment increases survival and prevents body weight loss in tumor-bearing animals: possible anti-cachectic effect. |
| Q57183649 | Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model |
| Q35690582 | TGF-β Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia |
| Q37590551 | The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia |
Search more.